HER-2 overexpression

T-DXd showed remarkable preclinical activity against HER2 FISH-negative, IHC-low EEC both in-vitro and in-vivo. These findings support its use beyond HER2-high expression and may represent a novel and effective treatment option for patients with HER2-low EEC who have progressed on standard chemotherapy and immunotherapy.

P2, N=9, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=28 --> 9

P2, N=42, Recruiting, Gruppo Oncologico del Nord-Ovest

P2, N=38, Not yet recruiting, Emory University

No 30-day postoperative mortality was observed. Conclusion Modified radical mastectomy remains a safe and effective surgical option for breast cancer management in resource-limited settings, providing acceptable morbidity and reliable short-term outcomes, particularly among patients presenting with advanced disease.

Of two patients with the HER2-ultralow phenotype, one was alive with no evidence of disease at 16 months follow-up. The results support the idea that HER2/neu overexpression is exceptionally rare in LGSOC; nevertheless, future trials are essential to fully characterize the spectrum of HER2/neu alterations in LGSOC and to determine definitively whether the rare cases with mutations or ultralow expression could represent a small subgroup that might benefit from specific targeted agents.

This Delphi study found strong consensus on key concepts for sampling, pathological testing, interpretation, and reporting of HER2-low and ultralow breast cancer. While the opinions expressed align with current guidelines, more evidence on the clinicopathological implications is needed.

P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2026 --> Jul 2030 | Trial primary completion date: Dec 2026 --> Jun 2026

The combined data indicate that ErbB2, perhaps by driving micronuclei formation, has immunogenic properties that manifest in the form of increased T-cell infiltration and expansion, which can be exploited therapeutically by combining PD1-directed checkpoint blockade with ErbB2-targeted therapy.

Thus, activated Ras can enhance the oncogenic effect of ErbB2 and NCL. These findings can be used to develop new ways to treat tumors that overexpress ErbB2/nucleolin and mutant Ras.

P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting

Unexpectedly, dual-ligand AaLS protein nanoparticles (AaLS/TRAIL/A10 and AaLS/TRAIL/2Rb17C) exhibited biphasic cytotoxicity; low doses synergistically enhanced apoptosis in HER2-positive cells, whereas higher doses reduced efficacy, likely due to the activation of survival signaling. These results highlight the importance of dose optimization for maximizing the use of TRAIL-based targeted therapies.